Sarah Turpin-Nolan

Sarah Turpin-Nolan

Auto-generated profile, based on publicly available information

Sarah Turpin-Nolan

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Cell Metabolism
Verified
Journal Article
Closed access
STSarah M. Turpin
Sarah M. Turpin
HNHayley T. Nicholls
Hayley T. Nicholls
DWDiana M. Willmes
Diana M. Willmes
AMArnaud Mourier
Arnaud Mourier
SBSusanne Brodesser
Susanne Brodesser
JBJens C. Brüning
Jens C. Brüning

1 January 2019 in Cell Reports
Verified
Journal Article
Open access
STSarah M. Turpin-Nolan
Sarah M. Turpin-Nolan
PHPhilipp Hammerschmidt
Philipp Hammerschmidt
WCWeiyi Chen
Weiyi Chen
AJAlexander Jais
Alexander Jais
KTKatharina Timper
Katharina Timper
JBJens C. Brüning
Jens C. Brüning
Skeletal muscle accumulates ceramides in obesity, which contribute to the development of obesity-associated insulin resistance. However, it remained unclear which distinct ceramide species in this organ contributes to instatement of systemic insulin resistance. Here, ceramide profiling of high-fat diet (HFD)-fed animals revealed increased skeletal muscle C18:0 ceramide content, concomitant with increased expression of ceramide synthase (CerS)1. Mice lacking CerS1, either globally or specifically in skeletal muscle (CerS1ΔSkM), exhibit reduced muscle C18:0 ceramide content and significant improvements in systemic glucose homeostasis. CerS1ΔSkM mice exhibit improved insulin-stimulated suppression of hepatic glucose production, and lack of CerS1 in skeletal muscle improves systemic glucose homeostasis via increased release of Fgf21 from skeletal muscle. In contrast, muscle-specific deficiency of C16:0 ceramide-producing CerS5 and CerS6 failed to protect mice from obesity-induced insulin resistance. Collectively, these results reveal the tissue-specific function of distinct ceramide species during the development of obesity-associated insulin resistance.

1 July 2009 in Cell Metabolism
Verified
Journal Article
Closed access
SCSeamus Crowe
Seamus Crowe
LWLindsay E. Wu
Lindsay E. Wu
CECatherine Economou
Catherine Economou
STSarah M. Turpin
Sarah M. Turpin
MMMaria Matzaris
Maria Matzaris
MWMatthew J. Watt
Matthew J. Watt

1 December 2006 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
STSarah M. Turpin
Sarah M. Turpin
GLGraeme I. Lancaster
Graeme I. Lancaster
IDIan Darby
Ian Darby
MFMark A. Febbraio
Mark A. Febbraio
MWMatthew J. Watt
Matthew J. Watt
Fatty acid-induced apoptosis occurs in pancreatic β-cells and contributes to the metabolic syndrome. Skeletal muscle insulin resistance is mediated by fatty acid oversupply, which also contributes to the metabolic syndrome. Therefore, we examined whether fatty acids induce apoptosis in skeletal muscle myotubes, the proapoptotic signaling involved, and the effects on insulin sensitivity. Exposure of L6 myotubes to palmitate induced apoptosis, as demonstrated by increased caspase-3 activation, phosphatidylserine exposure on the plasma membrane, and terminal deoxynucleotide transferase dUTP nick end labeling and DNA laddering, both markers of DNA fragmentation. Ceramide content was concomitantly increased, indicating a potential role for ceramides in palmitate-induced apoptosis. Supporting this notion, reducing stearoyl-CoA desaturase-1 (SCD-1) protein content with short interfering RNA resulted in ceramide accumulation and was associated with increased apoptosis in the absence of palmitate. Furthermore, the membrane-permeable C2-ceramide enhanced apoptosis in myotubes, whereas the ceramide synthase inhibitor, fumonisin B1, abrogated the proapoptotic effects of palmitate. Insulin-stimulated glucose uptake was inhibited by palmitate treatment, whereas the addition of effector caspase inhibitors [Ac-DEVD-aldehyde (DEVD-CHO), Z-DQMD-FMK] independently restored >80% of the insulin-stimulated glucose uptake. These effects were observed independently from changes in the protein content of insulin signaling proteins, suggesting that proteosomal degradation is not involved in this process. We conclude that lipoapoptosis occurs in skeletal muscle myotubes, at least partially via de novo ceramide accumulation, and that inhibiting downstream apoptotic signaling improves glucose uptake in vitro.

15 September 2010 in Diabetologia
Verified
Journal Article
Closed access
PDF file
STS. M. Turpin
S. M. Turpin
AHAndrew Hoy
Andrew Hoy
RBR. D. Brown
R. D. Brown
CRC. Garcia Rudaz
C. Garcia Rudaz
JHJ. Honeyman
J. Honeyman
MWM. J. Watt
M. J. Watt

31 March 2009 in The Journal of Physiology
Verified
Journal Article
Closed access
STS. M. Turpin
S. M. Turpin
JRJ. G. Ryall
J. G. Ryall
RSR. Southgate
R. Southgate
IDI. Darby
I. Darby
AHA. L. Hevener
A. L. Hevener
MWM. J. Watt
M. J. Watt